It’s a simple question that physicians usually do not ask their patients: “When was your last drink?” “If the patient says yesterday, you know the patient isn’t a casual drinker,” said Joe G. Zein, MD ...

“If we can own rights again, which we know we can, the next question becomes, ‘what rights do we want to own?'” Grant said. “As it relates to the creation of content, obviously what always has broken ...

In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...

Independent news. Trusted by Texans. About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics | Republish Our Work | Jobs | Awards | Corrections | Strategic Plan | Downloads | ...

Chronic obstructive pulmonary disease, or COPD, is often thought of as a condition that only affects longtime smokers. In reality, the disease reaches far beyond that group. Women are ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Worried about what's in your tap water? A high-performing reverse osmosis (RO) countertop system is one of the best ways to protect your family. Unlike basic filters, these advanced systems are ...

Reverse osmosis (RO) is a vital water purification technology used in various applications such as boiler feedwater treatment, cooling water systems, and wastewater recycling. The feedwater for RO can ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...

“This new COPD diagnostic schema, which includes chest imaging, respiratory symptoms and spirometry, identified additional individuals at risk of poor respiratory outcomes,” said Bhatt, a professor in ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major $12 billion biobucks deal designed to strengthen the pharma’s offering for the ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...